Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150

Abpro Holdings, Inc.

Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.
CT-P72/ABP-102 demonstrated potent anti-tumor activity in HER2-high models, including Enhertu-resistant tumors.
Dual-affinity engineering reduced on-target/off-tumor activity; favorable safety in non-human primates.
Data supports advancement toward IND and first-in-human trial planned for next year.
Built on Abpro's DiversImmune® platform for rapid engineering of next-generation antibodies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.